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What is known about this subject?
1. Persistence with medicines can be considered as an outcome of a conscious decision patients 48 make about whether the continued taking of the medication will increase their utility 49 2. Discrete choice experiments of implementation of dosing have found that patients are willing to 50 accept adverse events in exchange for increase benefit.
INTRODUCTION

59
Medication adherence encompasses the processes of initiation, implementation of dosing and 60 persistence [1] . Reduced persistence with prescribed treatment is prevalent, with median length of 61 time between patients' initiation of treatment for chronic diseases and their last dose being typically in 62 the order of 1 year [2] , despite failure to continue treatment having a detrimental effect on health [3] .
63
Reasons for the premature discontinuation of medicines are varied, and include factors related to 64 patients, such as their beliefs and socioeconomic characteristics; the condition and its treatment; 65 healthcare professionals and health systems [3, 4] . There is emerging evidence of the role of 66 behavioural economic theories in explaining patients' choice to persist with their prescribed medicines 67 [5] . This is based on a notion that persistence with medications may be an outcome of a decision 68 patients consciously make about whether the continued taking of their medication will increase their 69 utility [6] . That is, if patients' utility (satisfaction) is maximised through taking their medications, their 70 likelihood of persisting increases; but conversely if patients maximise their utility by not taking their 71 medications, they will discontinue treatment.
72
Patients' utility may be examined using stated preference techniques, such as the discrete choice 73 experiment (DCE) [7] . DCEs are an attribute-based survey measure underpinned by a Lancastrian 74 view of utility which contends that goods and services (or medicines in this case) can be described by 75 their characteristics or attributes and that the utility yielded by a medicine is a function of its various 76 attributes [8] . Choices reveal information about the relative importance of each attribute, willingness 77 to trade them, and total utility which patients aim to maximise. Concurrent assessment of influences on patients' decisions to persist with a medication in terms of 117 the utility they derive from medication characteristics, and theory driven psychosocial characteristics 118 associated with medication preferences, increases the possibilities for interventions which could be 119 both medicine and person-based. We are unaware of any study in which a range of health 120 psychology theories have been tested simultaneously alongside preference elicitation methods in 121 relation to medication persistence.
122
This study aims to (i) assess how patients from across Europe value the key attributes of medicines in 123 their stated decision to persist with taking them and to examine the trade-off between potential 124 benefit, harm and convenience; (ii) explore the relationship between these preferences and 125 psychosocial and sociocognitive characteristics.
127
METHODS
128
The study involved a multi-national, web-based survey of hypertensive adult patients containing a 129 DCE designed to elicit the preferences of patients for attributes of a hypothetical medication. The 130 survey was piloted and ethically approved for eleven European countries: Austria, Belgium, England,
131
France, Germany, Greece, Hungary, Netherlands, Poland, Portugal, and Wales. Patients were 132 eligible for the study if they self-reported as being 18 years or older, diagnosed by a doctor as having 133 hypertension that lasted at least 3 months, currently prescribed antihypertensive medication, and 134 personally responsible for administering their medication. Respondents were excluded if they were 135 aged less than 18 years, declared a psychiatric disorder, or lived in a nursing home or similar facility 136 where they were not responsible for their own medicines taking. The target sample was for a 137 minimum of 100 respondents per country (consistent with DCE studies [9,10]) up to a maximum of 138 323 patients per country [22] . Respondents were principally recruited using advertisements in 139 community pharmacies. Additional strategies included advertisements in hypertension clinics 140 (Hungary), GP surgeries (Hungary and Poland) and local press (England and Wales). The survey 141 was anonymous, hosted online and restricted to one respondent per Internet Protocol address. 142 143 DCE attributes, levels, and experimental design systematic review [9] . Attributes identified were categorised as follows: mild adverse drug reactions duration of treatment (n=4), location of treatment (n=3), cost (n=3), route of administration (n=1),
148
quality of life (n=1). The four most commonly used attributes were selected: treatment benefit, risk of 149 common mild adverse drug reactions (ADRs), risk of rare but potentially life-threatening ADRs and 150 dosage frequency (table 1).
151
We hypothesised that benefits would have a positive influence on patients' stated intention to persist 152 with treatment, while increased risk of harms and dose frequency would be negative.
153
Insert Table 1 here 154 Each attribute was set to have three levels, representative of treatments used commonly for the 155 management of chronic diseases. These were set at plausible values with a range sufficient to 156 encourage respondents to trade, and limit potential dominance (Table 1) , while allowing for scenarios Survey of psychosocial and sociocognitive factors 172 Validated self-report instruments were used to assess sociocognitive determinants of adherence [22] .
173
Illness representations were measured using the Brief Illness Perception Questionnaire (B-IPQ) [25] . 
188
Descriptions of ADR prevalence were taken from the European Medicines Agency's standard text for 189 summaries of product characteristics, which is available in all European languages. Treatment benefit and risk of mild ADR were included in the analysis as linear continuous variables.
200
We explored the assumption of linearity for frequency of dose and risk of severe ADR, using effects 201 coding and plotting the resulting size of the coefficient against the level of each attribute. The level of 202 the base case was calculated using the estimated levels: e.g.
203
βvery rare SEVERE_ADR = -(βrare SEVERE_ADR + βuncommon SEVERE_ADR)
204
The DCE contained two value attributes: treatment benefit and risk of common, mild ADR, that were 205 used to compare the rate at which patients were willing to give up a unit change in benefit or harm in 206 exchange for a unit change in another, whilst maintaining the same utility (marginal rates of 207 substitution, MRS). 95% confidence intervals were calculated by Bootstrapping with 1,000 208 replications. Lexicographic preferences were explored by looking for left or right hand bias, using 209 counts of how many respondents continually selected medicine A or B. The influence of psychosocial 210 and sociocognitive factors on preferences for persistence was assessed using exploratory subgroup 211 analyses. Subgroups were selected for analysis if they: (i) had a statistically significant association 212 with adherence (as defined by Morisky or MARS) [22] ; and (ii) were confirmed as significant predictors 213 of persistence in other published studies [14] . Log likelihood ratio tests of the base case regression 214 and the models comprising the two subgroups were performed at a 5% level of significance. If the 215 subgroup model was significantly different, the MRS for harms and benefits were calculated for each 216 category within the subgroup. 
220
The analysis was restricted to nine countries that reached the target sample size. There was an 221 inadequate level of available research support in France and Portugal that resulted in low response 222 (n=11, n=33 respectively) thus these were excluded. Eighty-nine percent (n=2,549) of people who (n=175), England (n=315), Germany (n=266), Greece (n=288), Hungary (n=322), Netherlands 225 (n=231), Poland (n=312) and Wales (n=319).
227
Sample characteristics
228
Participants' characteristics are presented in Table 2 . Respondents were split almost equally 229 according to gender (51% male) and employment status (52% employed), had a median age of 60 230 years, and were prescribed a median of 3 different medicines per day. The majority of patients (54%) 231 were prescribed medicines that required more than once-daily dosing.
232
Insert Table 2 
236
All four attributes influenced respondents' stated intention to persist with treatment (p<0.01) ( Table 3) .
237
Respondents were most likely to persist with the treatment offering greatest benefit (β=0.031), least 238 risk of mild but common ADRs (β=-0.023), or severe but rare ADRs (β=1.553), and the least frequent 239 dosing regimen (β=0.869). The signs and direction of the regression coefficients were consistent with 240 expectation.
241
Insert Table 3 here   242 All else being equal, the odds of patients stating that they would continue taking their medicines 243 increased by 3% for every 1 percentage point increase in the chance of treatment benefits, and 244 increased 2% for every 1 percentage point decrease in the risk of common mild side-effects. A 245 medicine with the lowest risk of severe ADR (very rare) increased the odds of persistence four-fold, 246 and the lowest dose frequency (once daily) more than two-fold.
248
Comparing preferences were willing to forego improvements in treatment benefits in order to: reduce the risk of severe ADR as opposed to a rare risk); reduce the frequency of dosing (forego 28.3 percentage point improvement 253 in treatment benefit for once-daily dosage frequency as opposed to twice daily); and to reduce the risk 254 of common mild side-effects (forego 7.4 percentage point improvement of treatment benefit for a 10 255 percentage point reduction in mild ADR) (Table 4 ). When considering harm as the value attribute, 256 respondents were also willing to accept an increase in risk of mild ADR to avoid severe ADR (68.6 257 percentage point increase in risk of mild side-effects for a 'very rare' risk of severe ADR as opposed 258 to rare); and to move to a less frequent dosing schedule (38.4 percentage point increase in risk of 259 mild ADR for once daily dose frequency as opposed to twice daily).
260
Insert Table 4 here 261 Exploratory analysis 262 Regressions controlling for psychosocial variables were significantly different from the base-case 263 regression in 10/12 cases (Appendix 2), but in each case, all four attributes were significant and in the 264 expected directions.
266
Respondents' willingness to trade treatment benefit for once daily dosing, as opposed to twice daily, 267 was significantly higher for respondents who were unlikely to take their medicines regularly. These 268 respondents, who had low intentions, were willing to forgo an additional 29.9 percentage point benefit 269 to take medication once, rather than twice a day (i.e. Appendix 2; MRS of lower intentions 49.97 270 minus MRS of high intentions 20.06). Individuals with high concerns about medicines were also 271 willing to forgo an additional benefit to take medication once, rather than twice a day (22.2 percentage 272 points); as where those who lacked confidence in their medicines-taking i.e. those with low self-273 efficacy (16.6 percentage points) and, those with higher illness concern (willing to forgo a 15.5
Respondents' willingness to trade treatment benefit for the lowest risk of ADR (very rare) opposed to 277 a rare risk was significantly higher for respondents who were (i) unlikely to take their medicines 278 regularly (people with low intention were willing to forgo a 32.4 percentage point additional benefit for 279 a very rare risk of severe ADR, than those categorised as high TPB intentions); (ii) demonstrated high 280 illness concern (24.5 percentage points); and (iii) had high concerns about medicines (23.8 281 percentage points). The results of the study suggest that, in addition to treatment benefits, patients place a high value on 286 reduced risk of severe (but relatively rare) ADRs and less frequent dosing when stating that they 287 choose to continue taking a medicine. Stated preference to persist is therefore associated with the 288 willingness to trade potential benefits for reduced harm and increased convenience. The total utility 289 produced by different combinations of these attributes may have value in assessing patients' 290 likelihood of persisting with medicines, in the context of health care provider-patient communications, 291 and the personalisation of medicines, or formulations thereof, to maximise persistence.
293
This study has shown that the evidence-based medicine model of health maximisation via use of 294 treatments with the highest expected net benefit may not necessarily result in the best outcome for 295 patients if there is misalignment in preferences. Persistence with medications can be considered as 296 an outcome of a decision patients make about whether the continued taking the medication will 297 increase their utility [6] . Maximising utility may therefore increase persistence, which may lead to 298 better health outcomeseven when using a less effective treatment. Our analysis therefore 299 suggests a mechanism via which the prescribing of alternative treatments might improve persistence 300 and hence health outcome. We have also found that patients' trade-offs between benefits, harm and 301 convenience are influenced by psychosocial and sociocognitive factors. Interventions to improve 302 persistence, grounded in theory and targeted towards psychosocial variables (e.g. barriers to 303 medicines, self-efficacy / confidence in medicines taking) may therefore improve the probability of persistence directly [22] , and indirectly through changing patients' preferences for medicines-related preferences for medications (not persistence with) suggest that attributes such as route of 333 administration [34], quality of life, location / provider, duration of treatment, among others, may also 334 have a significant influence on preference. The risk attributes were also presented as probabilities 335 with no indication of frequency or time horizon. It is acknowledged, however, that trading multiple 336 attributes is cognitively challenging [35] . We aimed to minimise this by piloting the DCE extensively 337 and by using two methods of displaying risk. Event frequencies were supplemented by pictograms 338 which were intended to aid interpretation by depicting probabilities graphically and colour-coding 339 positive and negative effects. Respondents find it much easier to understand pictorial representations 340 than presenting probabilities in the form of 1 in X chance [36] . Thirdly, the respondents were 341 diagnosed with hypertension whereas the DCE was aimed to cover a broad spectrum of 342 pharmaceuticals.. The DCE was not amenable to treatments for hypertension as they are mainly 343 once daily. Fourthly, the length of the survey (135 items) represents a further limitation, but 344 completion rates were high as the DCE was purposely put towards the beginning of the survey before 345 participants were asked to complete any items that may have conditioned their choice [22] . Finally, as 346 with any stated preference study, the findings need to be confirmed by studies of revealed preference.
348
Patients were willing to trade potential benefits, harms, and convenience in responding that they 
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Figures and Tables
Figure 1
Example of a pair wise choice question Gastrointestinal irritation is a common ADR for many treatments. Frequency based on representative range
Severe ADR Potentially lifethreatening sideeffects Very rare: 1 in 10,000 Rare: 1 in 1,000 Uncommon: 1 in 100
Likelihood of life-threatening ADRs are typically uncommon to very rare (-72.35, -63.98) Severe ADR -Rare -14.48 (-16.99, -12.77) 19.64 (17.49, 21.60) Severe ADR - 51.25) Dose -Once a day 28.29 (25.18, 33.11) -38.36 (-42.50, -34.77) Dose -Twice a day -9.63 (-11.88, -8.14) 13.05 (11.15, 15.33) Dose -Four times a day -18.66 (-21.51, -16.67) 25.31 (22.95, 27.60) Treatment benefit -1.36 (-1.49, -1.17) Common mild side-effects -0.74 (-0.85, -0.67) 504 1. Overall, how confident are you that you will always take your medications as prescribed? 2. Overall, how confident are you that you will always take your medications at the prescribed times? 1. Was there someone who reminded you to take your medicines? 2. Was there someone who helped you to prepare the medicines? 3. Was there someone who encouraged you to take your medicines correctly? 4. Was there someone who gave practical tips to make it easier for you to take your medicines? 5. Was there someone who adapted his or her own life habits (waking up, schedule…) to make it easier for you to take your medicines? Intention: Likely to and/or intend to take medicines
